Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

s or labeling in any market, or at any particular time. Nor can there be any guarantee that everolimus will achieve any particular levels of revenue in the future. In particular, management's expectations regarding everolimus could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations ac
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014 /PRNewswire/ ... Neuropathy Foundation (HNF), both philanthropies, announced today the ... candidates for the treatment of the rare disease ... BioPontis Alliance announced its alliance model earlier this ... first demonstration of a collaborative model where researchers ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
(Date:10/20/2014)... It’s hard to imagine what it’s like ... children around the world, it’s a reality. And while new ... are forced to walk barefoot on rocky terrain or sewage-lined ... with their friends. , Buckner International's Shoes for ... in October to encourage support for Air1 and while ...
(Date:10/20/2014)... October 20, 2014 Do you ever ... Here comes a wonderful app Metassessor for teachers, specialists ... company helped its client “Intervention Development LLC” to ... app is designed for iOS 4.3 or later and ... app is optimized for iPhone 5. It is now ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, BambooIndustry.com, ... has unveiled its new range of bamboo deckings ... for these natural items; they are now available at ... most people, it is hard to overstate the significance ... of attention to online services. The company’s workers are ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
(Date:10/19/2014)... October 20, 2014 SweetDressy.com, a professional ... announced its promotion for long evening dresses . ... the special offer; the current discount is up to ... the industry pioneers in the fashion field. Its dress ... ladies dwelling in various parts of the world. All ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... Senegal, March 25 The U.S. Agency for ... Assistance (OFDA) is providing more than $3.7 million ... increase food security of families in Senegal.Of this ... improve community-based nutrition efforts and agriculture production in ...
... 25 Globus Medical, Inc., the largest privately ... announced the launch of MicroFuse(TM) ST Granules, a ... both strength and porosity. MicroFuse(TM) technology utilizes proprietary ... polymers manufactured with a patented microsphere process to ...
... Several cases of inappropriate shocks from appliances have ... -- A literally shocking tale of the potential ... implanted defibrillators comes from cardiologists in Denmark. , ... receiving an implantable cardioverter defibrillator, was readmitted shortly ...
... NATICK, Mass., March 25 Boston Scientific Corporation (NYSE: ... Poor,s Ratings Services has raised the Company,s rating outlook ... credit rating at BB+.The Standard and Poor,s upgrade follows ... the Company,s outlook to stable from negative.Standard and Poor,s ...
... Neonatologists begin new era of treatment to save tiniest babiesCLEVELAND, March 25 ... NICU provides individual rooms with sleep accommodations so parents can stay ... Innovative care design that creates a healing environment with ... Green building materials incorporated throughout NICU. , ...
... One of the Highest Civilian Honors Given to ... March 25 The Congressional Medal of Honor ... Above & Beyond Citizen Honors recipients for ... process, three Americans have been selected for their ...
Cached Medicine News:Health News:Globus Medical's MicroFuse(TM) Technology Engineered for Optimal Strength and Porosity 2Health News:Faulty Household Wiring Can Trigger a Heart Defibrillator 2Health News:Standard and Poor's Raises Boston Scientific's Rating Outlook to Positive 2Health News:Standard and Poor's Raises Boston Scientific's Rating Outlook to Positive 3Health News:Rainbow Babies & Children's Hospital Opens Most Technologically Advanced NICU in World 2Health News:Rainbow Babies & Children's Hospital Opens Most Technologically Advanced NICU in World 3Health News:Rainbow Babies & Children's Hospital Opens Most Technologically Advanced NICU in World 4Health News:'Above & Beyond Citizen Honors' Announces and Honors 2009 Recipients 2Health News:'Above & Beyond Citizen Honors' Announces and Honors 2009 Recipients 3Health News:'Above & Beyond Citizen Honors' Announces and Honors 2009 Recipients 4
... ,The Cardiocap/5 is a compact, ... the operating room, ambulatory surgery unit, ... offers full vital signs monitoring capabilities ... circulation to advanced airway gas analysis ...
... Releasing the power of clinical information. ... newest generation of clinical connectivity solutions that ... provide effective, high-quality patient care. You will ... be able to share it with your ...
... of clinical information. , ,S/5 Clinical ... connectivity solutions that help you and your ... care. You will have access to essential ... it with your care team and specialists, ...
... Compact and comprehensive solution for ... Arrhythmia Workstation (ARRWS) provides one compact, ... telemetry monitored patients. It connects to ... analysis for up to 16 beds., ...
Medicine Products: